secwatch.observer — SEC 8-K summary
======================================

Issuer:     SQZ Biotechnologies Co (—)
CIK:        0001604477
Form:       8-K
Filed at:   2022-11-30T23:59:59+00:00
Accession:  0000950170-22-025877
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SQZ Biotechnologies Focuses on eAPC Program, Cuts Workforce 60%, CEO Sharei Steps Down
--------------------------------------------------------------------------------

- Workforce reduction of approximately 60%, expected to be substantially completed in January 2023.
- Estimated restructuring costs of $5 million for severance and employee-related benefits.
- CEO Armon Sharei stepped down effective Nov 30, 2022; Howard Bernstein appointed Interim CEO.
- CFO Micah Zajic to step down Dec 31, 2022; Richard Capasso named principal financial officer.
- Company pauses first-generation APC, AAC, TAC programs to focus on eAPC; data readout expected mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604477/000095017022025877/0000950170-22-025877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604477/000095017022025877/sqz-20221130.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-025877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer